21 Results for "

CYP450 enzymes

" in MedChemExpress (MCE) Product Catalog:
Products (21)

21 Results for "CYP450 enzymes" in MCE Product Catalog:

2
2 Cited Publications
Cat. No.: HY-B0653A
CAS No.: 27262-48-2
Synonyms: (S)-(-)-Bupivacaine monohydrochloride
Levobupivacaine hydrochloride ((S)-(-)-Bupivacaine monohydrochloride) is a long-acting amide local agent that can suppress or relieve pain. Levobupivacaine hydrochloride exerts agent that can suppress or relieve pain. and analgesic effects through reversible blockade of neuronal sodium channel. Levobupivacaine hydrochloride can inhibit impulse transmission and conduction in cardiovascular and other tissues, possessing certain cardiac and CNS toxicity. Levobupivacaine hydrochloride is metabolized by hepatic cytochrome P450 (CYP450) enzymes in vivo. Levobupivacaine hydrochloride can also induce ferroptosis by miR-489-3p/SLC7A11 signaling in gastric cancer .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-B0653
CAS No.: 27262-47-1
Synonyms: (S)-(-)-Bupivacaine
Research Areas:  

Neurological Disease Cancer

Levobupivacaine ((S)-(-)-Bupivacaine) is a long-acting amide local agent that can suppress or relieve pain. Levobupivacaine exerts agent that can suppress or relieve pain. and analgesic effects through reversible blockade of neuronal sodium channel. Levobupivacaine can inhibit impulse transmission and conduction in cardiovascular and other tissues, possessing certain cardiac and CNS toxicity. Levobupivacaine is metabolized by hepatic cytochrome P450 (CYP450) enzymes in vivo. Levobupivacaine can also induce ferroptosis by miR-489-3p/SLC7A11 signaling in gastric cancer .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-N2071
CAS No.: 77-53-2
Synonyms: (+)-Cedrol; α-Cedrol
Cedrol is a potent competitive inhibitor of cytochrome P-450(CYP) enzyme. Cedrol plays an anticancer role by inducing cell cycle arrest and Caspase-dependent apoptosis. Cedrol acts as a neutrophil agonist that can desensitize cells to subsequent stimulation of N-formyl peptides. Cedrol prevents neuropathic pain caused by chronic contractile injury by inhibiting oxidative stress and inflammation. In addition, Cedrol has antibacterial, hair loss prevention and anti-anxiety properties .
loading...
    loading...
Cat. No.: HY-113482
CAS No.: 80434-32-8
Synonyms: 1β-OH-DCA
1β-Hydroxydeoxycholic acid (1β-OH-DCA), a secondary bile acid, is a CYP3A biomarker. Deoxycholic acid is specifically metabolized into 1β-Hydroxydeoxycholic acid by CYP3A4 and CYP3A7 using recombinant human CYP450 enzymes .
loading...
    loading...
Cat. No.: HY-N1282
CAS No.: 480-81-9
Seneciphylline is an orally effective hepatotoxic inducer. Seneciphylline is metabolized by CYP450 enzymes into active intermediates, which covalently bind to intracellular biomacromolecules such as proteins and DNA to form adducts, which in turn trigger a series of toxic reactions, such as inducing cell apoptosis and damaging mitochondrial function. Seneciphylline can be used in hepatotoxicity research[1][2].
loading...
    loading...
Cat. No.: HY-149669
CAS No.: 3053430-96-6
Purity:  99.29%
Research Areas:  

Cancer

PH14 is a PI3Kα/HDAC3 inhibitor, with an IC50 value of 20.3 nM against PI3Kα and 24.5 nM against HDAC3. PH14 blocks the phosphorylation of AKT, inhibits the PI3K/AKT signaling pathway, increases the level of acetylated histone H3, promotes apoptosis, and exerts antiproliferative activity against tumor cells. PH14 can be used in the research of mantle cell lymphoma, myeloma, acute promyelocytic leukemia, and breast cancer .
loading...
    loading...
Cat. No.: HY-178780
CAS No.: 2137977-29-6
Synonyms: MKP10241
Target:  

GPR119

Deziglipel (MKP10241) is an orally active GPR119 agonist (human EC50: 3.7 nM; IC50 > 7.2 μM). Deziglipel activates GPR119 to increase cAMP levels, promotes active GLP-1 release, reduces blood glucose and HbA1c, decreases body weight and feed intake, and resolves MASH via altered lipid, cytokine, and liver enzyme levels. Deziglipel shows low hERG channel inhibition, minimal CYP450 inhibition, no PXR activation, and no significant transporter inhibition. Deziglipel can be used for the research of type 2 diabetes mellitus, obesity, MASH/MASLD, and metabolic disorders .
loading...
    loading...
Cat. No.: HY-N16478
CAS No.: 174285-73-5
Echihumiline is an alkaloid targeting hepatic cytochrome P450 enzymes (CYP450). Echihumiline induces DNA cross-linking and oxidative stress in hepatocytes, leading to liver necrosis and fibrosis. Echihumiline is promising for research of liver diseases .
loading...
    loading...
Cat. No.: HY-W803860
CAS No.: 86383-21-3
Research Areas:  

Cardiovascular Disease

N-Depropylpropafenone is an active metabolite of Propafenone (HY-B0432), generated through the CYP450 enzyme system (mainly CYP2D6). It functions by blocking sodium ion channels, slowing myocardial conduction and exhibiting certain antiarrhythmic effects .
loading...
    loading...
Cat. No.: HY-178479
CAS No.: 2581050-29-3
IDO1-IN-30 (Compound (R)-100) is a potent and highly selective IDO1 inhibitor. IDO1-IN-30 has an IC50 of 4.8 nM to IDO1 in SKOV3 cells. IDO1-IN-30 does not show significant cytotoxicity at 25 µM in HepG2 cells. IDO1-IN-30 can eliminate inhibition of CYP450 enzymes (such as 3A4, 2C9, 2D6). IDO1-IN-30 can be used for research on cancer and inflammatory conditions .
loading...
    loading...
Cat. No.: HY-B0653AS
Synonyms: (S)-(–)-Bupivacaie-d9hydrochloride
Levobupivacaine-d9 ((S)-(–)-Bupivacaie-d9) hydrochloride is deuterium labeled Levobupivacaine hydrochloride (HY-B0653A). Levobupivacaine hydrochloride ((S)-(-)-Bupivacaine monohydrochloride) is a long-acting amide local agent that can suppress or relieve pain. Levobupivacaine hydrochloride exerts agent that can suppress or relieve pain. and analgesic effects through reversible blockade of neuronal sodium channel. Levobupivacaine hydrochloride can inhibit impulse transmission and conduction in cardiovascular and other tissues, possessing certain cardiac and CNS toxicity. Levobupivacaine hydrochloride is metabolized by hepatic cytochrome P450 (CYP450) enzymes in vivo. Levobupivacaine hydrochloride can also induce ferroptosis by miR-489-3p/SLC7A11 signaling in gastric cancer .
loading...
    loading...
Cat. No.: HY-175075
CAS No.: 2567591-82-4
Target:  

Drug Metabolite

Research Areas:  

Others

(±)11(12)-EET Ethanolamide is a potential metabolite of Anandamide (HY-10863), and it is produced by the catalysis of cytochrome P450 (CYP450) enzymes .
loading...
    loading...
Cat. No.: HY-181407
Herbicide safener-5 is a herbicide (Herbicide) safener. Herbicide safener-5 promotes plant growth recovery, enhances the activities of detoxifying enzymes (ALS, GST, CYP450, POD), and reduces SOD activity. Herbicide safener-5 is applicable to herbicide-related research .
loading...
    loading...
Cat. No.: HY-N2071R
CAS No.: 77-53-2
Synonyms: (+)-Cedrol (Standard); α-Cedrol (Standard)
Cedrol (Standard) is the analytical standard of Cedrol. This product is intended for research and analytical applications. Cedrol is a potent competitive inhibitor of cytochrome P-450(CYP) enzyme. Cedrol plays an anticancer role by inducing cell cycle arrest and Caspase-dependent apoptosis. Cedrol acts as a neutrophil agonist that can desensitize cells to subsequent stimulation of N-formyl peptides. Cedrol prevents neuropathic pain caused by chronic contractile injury by inhibiting oxidative stress and inflammation. In addition, Cedrol has antibacterial, hair loss prevention and anti-anxiety properties.
loading...
    loading...
Cat. No.: HY-117593
CAS No.: 1369591-04-7
Research Areas:  

Cancer

NSC 23925B is a P-glycoprotein (P-gp) inhibitor, as well as the most biologically active isomer of NSC23925 (HY-19626), which reverses and prevents P-glycoprotein-mediated multidrug resistance in cancer cells. NSC 23925B shows weak inhibition against most CYP450 enzymes (IC50 > 10 μM), and exhibits moderate inhibitory activity against CYP2B6 and CYP2D6 with IC50 values of 8.589 μM and 1.407 μM, respectively. NSC 23925B can be used for the research of multidrug-resistant cancers .
loading...
    loading...
Cat. No.: HY-178479A
Target:  

Drug Isomer

Research Areas:  

Others

(Rac)-IDO1-IN-30 is the Rac isomer of IDO1-IN-30 (HY-178479). IDO1-IN-30 is a potent and highly selective IDO1 inhibitor. IDO1-IN-30 has an IC50 of 4.8 nM to IDO1 in SKOV3 cells. IDO1-IN-30 does not show significant cytotoxicity at 25 µM in HepG2 cells. IDO1-IN-30 can eliminate inhibition of CYP450 enzymes (such as 3A4, 2C9, 2D6). IDO1-IN-30 can be used for research on cancer and inflammatory conditions .
loading...
    loading...
Cat. No.: HY-181543
CAS No.: 2925663-26-7
Target:  

CD38

Research Areas:  

Neurological Disease

CVN14 is a potent, selective and brain-penetrant CD38 inhibitor with human IC50 19 nM, mouse IC50 2.4 nM. CVN14 binds uncompetitively to form a complex with CD38 and ADPR, and inhibits CD38 enzymatic activity. CVN14 can be used for the research of neurodegenerative diseases .
loading...
    loading...
Cat. No.: HY-184735
CAS No.: 2924270-62-0
Target:  

Fungal Cytochrome P450

Research Areas:  

Infection

Antifungal agent-170 is an Antifungal agent. Antifungal agent-170 potently inhibits the growth of recombinant Saccharomyces cerevisiae strains expressing wild-type and mutant fungal CYP51 enzymes. Antifungal agent-170 potently inhibits the growth of Candida albicans, Candida glabrata, Candida krusei, Cryptococcus neoformans and Cryptococcus gattii. Antifungal agent-170 provides survival benefits in the Galleria mellonella (greater wax moth) infection model. Antifungal agent-170 can be used for the research of invasive fungal infections .
loading...
    loading...
Cat. No.: HY-187356
Synonyms: BI’7927
Target:  

mGluR

Research Areas:  

Neurological Disease

VU6052959 (BI’7927) is an orally active, blood-brain barrier-penetrant mGlu3 modulator with an EC50 of 36 nM in humans and 16 nM in rats. VU6052959 enhances recognition memory and reverses cognitive impairment in male rats. VU6052959 can be used in the research of schizophrenia .
loading...
    loading...
Cat. No.: HY-181662
CAS No.: 883012-32-6
Target:  

MAP3K

Research Areas:  

Neurological Disease

DLK-IN-2 is a selective inhibitor of DLK and neuroprotective agent. DLK-IN-2 shows no significant inhibition against CYPs 3A4, 2D6 and 2C9. DLK-IN-2 inhibits acute axonal palmitoylation of DLK, blocks DLK-dependent pro-degenerative axon-to-soma retrograde signaling and suppresses c-Jun phosphorylation. DLK-IN-2 can be used for the mechanistic study of neurodegenerative diseases .
loading...
    loading...